Targeted therapy before and after surgery for stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests giving targeted therapy pills before and after surgery for stage III lung cancer with certain rare gene changes. The goal is to see if this approach helps shrink or control the cancer better than surgery alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have stage III non-small cell lung cancer that can be removed with surgery (or might be after treatment).
- Your tumor has one of these rare gene changes: EGFR exon 20 insertion, ALK fusion, ROS1 fusion, MET exon 14 skipping, RET fusion, or KRAS G12C.
- You are generally able to care for yourself (ECOG 0-1) and have at least one measurable tumor.
- You have not had lung cancer treatment in the last 2 years or another cancer in the last 5 years.
- You have not had major surgery in the last 28 days, and you are willing to follow the study plan and give consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether removing the main lung tumor with surgery, combined with an EGFR-targeted pill, can help people with stage IV lung cancer that has a specific EGFR mutation. The goal is to improve outcomes compared with medication alone.
This trial tests a targeted therapy pill (called iruplinalkib) given before surgery for people with a certain type of lung cancer (ALK-positive NSCLC). The goal is to see if the pill can shrink the tumor, making it easier to remove completely during surgery.
This study tests whether giving a combination of three medicines before surgery can help shrink tumors in people with stage 2 or 3 non-small cell lung cancer, potentially making surgery and recovery more effective. The medicines include an immunotherapy drug (tislelizumab), a targeted therapy (anlotinib), and a chemotherapy drug (nab-paclitaxel).
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests a new targeted pill (zipalertinib) combined with standard chemotherapy (carboplatin and pemetrexed) before surgery for early-stage lung cancer with specific EGFR mutations. It aims to shrink the tumor and potentially improve outcomes after surgery.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.